← All trials
NCT05827614
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 24, 2023
- Primary completion
- Jan 31, 2025
- Completion date
- Jan 31, 2026
- First posted
- Apr 25, 2023
- Last posted
- May 9, 2023
- Enrollment
- 47
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boundless BioLead sponsor
- Boundless BioStudy director
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Squamous Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Leiomyosarcoma
- Liposarcoma
- Lung Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.